Kuroki Toshihide, Ishibashi Hiroki
Seishin Shinkeigaku Zasshi. 2015;117(1):42-8.
A growing body of evidence suggests the significant efficacy of behavioral activation therapy (BA) for the treatment of depression, although BA had formerly been regarded as only a part of the techniques for cognitive-behavioral treatment (CBT). The aim of this article is to review the effectiveness, indications, and limitations of BA for the psychosocial treatment of depression. The research group of Washington University in St. Louis, who previously suggested the marked efficacy of BA based on component analysis of CBT, performed a large-scale study to compare the effect of BA and cognitive therapy (CT) or antidepressant medication on the acute phase of depression. As the results, BA was superior to CT and comparable to antidepressant medication in acute-phase treatment for a subgroup of patients with relatively severe depression. Moreover, a long-term follow-up study revealed a benefit of BA compared to pharmacological treatment in regard to the persistence of the effect and cost-effectiveness. More recently, a number of meta-analyses have indicated no significant difference among BA and other psychotherapies regarding their efficacy for the treatment of depression. Because BA does not require patients or therapists to learn complex skills and is also time-efficient, it is recommended as the first-line treatment for mild or moderate depression. However, further studies are needed to consider indications, the timing of induction, and variation in BA techniques if it is applied for the treatment of depression in a general clinical setting in Japan.
越来越多的证据表明行为激活疗法(BA)在治疗抑郁症方面具有显著疗效,尽管BA以前仅被视为认知行为疗法(CBT)技术的一部分。本文旨在综述BA在抑郁症心理社会治疗中的有效性、适应症和局限性。圣路易斯华盛顿大学的研究小组此前基于CBT的成分分析提出了BA的显著疗效,他们进行了一项大规模研究,比较BA与认知疗法(CT)或抗抑郁药物在抑郁症急性期的效果。结果显示,在对一组病情相对严重的抑郁症患者进行急性期治疗时,BA优于CT,且与抗抑郁药物效果相当。此外,一项长期随访研究表明,与药物治疗相比,BA在疗效持久性和成本效益方面具有优势。最近,一些荟萃分析表明,BA与其他心理疗法在治疗抑郁症的疗效上没有显著差异。由于BA不需要患者或治疗师学习复杂技能,而且省时高效,因此被推荐作为轻度或中度抑郁症的一线治疗方法。然而,如果在日本的一般临床环境中应用BA治疗抑郁症,还需要进一步研究以考虑其适应症、诱导时机以及BA技术的差异。